What is the survival rate of deciduous molars in cases with agenesis of premolar successors? A systematic review.


Journal

The Angle orthodontist
ISSN: 1945-7103
Titre abrégé: Angle Orthod
Pays: United States
ID NLM: 0370550

Informations de publication

Date de publication:
01 01 2022
Historique:
accepted: 01 05 2021
received: 01 12 2020
pubmed: 31 7 2021
medline: 24 12 2021
entrez: 30 7 2021
Statut: ppublish

Résumé

To systematically review the literature on the survival rate of deciduous molars in cases of agenesis of premolar successors. Four electronic databases and partial grey literature were searched up to November 2020. The PECOS eligibility criteria included (P) second deciduous molar (E) exposed to agenesis of a premolar successor (O) evaluated by the survival rate in the oral cavity, infraocclusion, and root resorption through (S) observational studies. Risk of bias (RoB) was assessed using the checklists from the Joanna Briggs Institute and the level of evidence was assessed using the GRADE (Grading of Recommendations, Assessment, Development and Evaluations) tool. Three studies were included: one with low, one with moderate, and one with high RoB. Synthesis methods included the frequency of persistent deciduous second molars during the follow-up. Approximately 82% to 89% remained in the oral cavity after 5 to 13 years. The incidence of root resorption was 11%, and the infraocclusion was 1 mm. The level of evidence was considered low for each outcome. There was considerable RoB regarding the observational studies and a need for clinical and radiographic monitoring of the deciduous molars. Maintaining a deciduous molar in the oral cavity in patients with agenesis of the premolar successor is a viable clinical choice since 82% to 89% of the retained molars evaluated were in good condition over a follow-up ranging from 5 to 13 years. Infraocclusion and root resorption did not seem to increase considerably. The level of evidence was considered low for each outcome.

Identifiants

pubmed: 34329385
pii: 468475
doi: 10.2319/123020-1039.1
pmc: PMC8691466
doi:

Types de publication

Journal Article Systematic Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

110-117

Informations de copyright

© 2022 by The EH Angle Education and Research Foundation, Inc.

Références

Am J Orthod Dentofacial Orthop. 2020 Apr;157(4):571-583.e16
pubmed: 32241364
Br J Oral Maxillofac Surg. 2019 Jun;57(5):397-406
pubmed: 31076220
J Dent Res. 1963 Mar-Apr;42:660-74
pubmed: 13939388
BMJ. 2008 Apr 26;336(7650):924-6
pubmed: 18436948
BMC Oral Health. 2020 Mar 30;20(1):92
pubmed: 32228667
Am J Orthod Dentofacial Orthop. 2006 Oct;130(4):437-44
pubmed: 17045142
Eur J Orthod. 2019 Nov 21;:
pubmed: 31750517
Am J Orthod Dentofacial Orthop. 2001 Mar;119(3):202-10
pubmed: 11244413
Dentomaxillofac Radiol. 1975 Jan;4(1):70
pubmed: 25629875
Eur J Orthod. 2000 Jun;22(3):245-55
pubmed: 10920557
JBI Evid Synth. 2020 Oct;18(10):2127-2133
pubmed: 33038125
Int J Implant Dent. 2015 Dec;1(1):30
pubmed: 27747652
Am J Orthod Dentofacial Orthop. 2020 Oct;158(4):587-598
pubmed: 32839074
Am J Orthod. 1985 Jan;87(1):46-55
pubmed: 3855349
Int J Oral Maxillofac Surg. 2016 May;45(5):610-7
pubmed: 26696138
Eur J Orthod. 1984 May;6(2):123-31
pubmed: 6587969
Eur J Orthod. 2007 Apr;29(2):210-6
pubmed: 17489002
Eur J Orthod. 2008 Jun;30(3):254-61
pubmed: 18540014
Am J Orthod Dentofacial Orthop. 2004 May;125(5):537-43
pubmed: 15127021
Community Dent Oral Epidemiol. 2004 Jun;32(3):217-26
pubmed: 15151692
Eur J Orthod. 2000 Jun;22(3):239-43
pubmed: 10920556
Am J Orthod Dentofacial Orthop. 2002 Feb;121(2):110-9; quiz 193
pubmed: 11840123
Eur J Prosthodont Restor Dent. 2018 Mar 01;26(1):2-15
pubmed: 29461745

Auteurs

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH